Transient monocular blindness and antiphospholipid antibodies in systemic lupus erythematosus

被引:14
|
作者
Donders, RCJM
Kappelle, LJ
Derksen, RHWM
Algra, A
Horbach, DA
de Groot, PG
van Gijn, J
机构
[1] Univ Utrecht Hosp, Dept Neurol, NL-3584 CX Utrecht, Netherlands
[2] Univ Utrecht Hosp, Dept Rheumatol & Clin Immunol, NL-3584 CX Utrecht, Netherlands
[3] Univ Utrecht Hosp, Julius Ctr Patient Oriented Res, NL-3584 CX Utrecht, Netherlands
[4] Univ Utrecht Hosp, Dept Hematol, NL-3584 CX Utrecht, Netherlands
关键词
D O I
10.1212/WNL.51.2.535
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Objective: Among patients with systemic lupus erythematosus (SLE), the presence of antiphospholipid antibodies (APA), notably the lupus anticoagulant, and anticardiolipin antibodies (aCL) characterizes a subset of patients with a thrombotic tendency. During the regular follow-up care of patients with SLE, we noticed that many described transient visual disturbances. Because a hypercoagulable state may cause transient monocular blindness (TMB), we determined the frequency of TMB and studied its relation to the presence of APA in patients with SLE. Methods: We asked 175 unselected patients with SLE whether they had transient visual disturbances and reviewed their medical charts. All patients were examined with specific attention to the presence of livedo reticularis. Blood was examined for APA. Results: Visual disturbances were recorded for 136 (78%) patients. According to predefined criteria, the symptoms were diagnosed as TMB for 10 (6%) patients and as visual disturbances associated with migraine for 18 (10%) patients. Five of the 10 patients with TMB had attacks in either eye. The 175 patients with SLE accrued a maximum total of 6,349 patient years in their lifetime. From this, the incidence of TMB can be calculated to be at least 158 per 100,000 per year. Lupus anticoagulant was detected in 3 of 10 patients with TMB and 41 of 165 patients without TMB (odds ratio, 1.3; 95% CI, 0.2 to 6.0). aCLs were found in 5 of 10 patients with TMB and 91 of 165 patients without TMB (odds ratio, 0.8; 95% CI, 0.2 to 3.7). Conclusions: The frequency of TMB among patients with SLE is at least 158 per 100,000 compared with the normal population (14 per 100,000 per year). However, among patients with SLE, no significant relation could be shown between TMB and the presence of APA or livedo reticularis.
引用
收藏
页码:535 / 540
页数:6
相关论文
共 50 条
  • [41] Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus
    Tomas, JF
    Alberca, I
    Tabernero, MD
    Cordero, M
    Del Pino-Montes, J
    Vicente, V
    JOURNAL OF RHEUMATOLOGY, 1998, 25 (01) : 57 - 62
  • [42] REPEATED STROKES, ANTIPHOSPHOLIPID ANTIBODIES AND SYSTEMIC LUPUS-ERYTHEMATOSUS
    FELDMAN, L
    SAVEUSE, H
    DECHY, H
    HOUBOUYAN, L
    LESUR, G
    PIETTE, JC
    ROUVEIX, E
    DORRA, M
    ANNALES DE MEDECINE INTERNE, 1991, 142 (07): : 543 - 544
  • [43] Antiphospholipid Antibodies and the Risk of Damage Accrual in Systemic Lupus Erythematosus
    Taraborelli, Mara
    Leuenberger, Laura
    Lazzaroni, Maria Grazia
    Martinazzi, Nicole
    Zhang, Wei
    Salmon, Jane E.
    Franceschini, Franco
    Tincani, Angela
    Erkan, Doruk
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [44] Myelopathy in systemic lupus erythematosus associated with antiphospholipid antibodies.
    Feki, I
    benHmida, M
    Masmoudi, H
    Triki, C
    Bahloul, Z
    Hachicha, J
    Jlidi, R
    Mhiri, C
    REVUE NEUROLOGIQUE, 1997, 153 (02) : 138 - 140
  • [45] The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus
    Taraborelli, M.
    Leuenberger, L.
    Lazzaroni, M. G.
    Martinazzi, N.
    Zhang, W.
    Franceschini, F.
    Salmon, J.
    Tincani, A.
    Erkan, D.
    LUPUS, 2016, 25 (12) : 1365 - 1368
  • [46] Impact of antiphospholipid antibodies on cardiovascular disease in systemic lupus erythematosus
    Farzaneh-Far, A
    Roman, MJ
    Lockshin, MD
    Devereux, RB
    Paget, SA
    Crow, MK
    Davis, A
    Sammaritano, L
    Levine, DM
    Salmon, JE
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 277A - 277A
  • [47] SYSTEMIC LUPUS-ERYTHEMATOSUS, ANTIPHOSPHOLIPID ANTIBODIES AND MALIGNANT HYPERTENSION
    CACOUB, P
    WECHSLER, B
    PIETTE, JC
    BEAUFILS, H
    COHEN, P
    HERREMAN, G
    BLETRY, O
    GODEAU, P
    ANNALES DE MEDECINE INTERNE, 1994, 145 (01): : 50 - 52
  • [48] Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies
    Descloux, E.
    Durieu, I.
    Cochat, P.
    Durand, D. Vital
    Ninet, J.
    Fabien, N.
    Cimaz, R.
    RHEUMATOLOGY, 2008, 47 (02) : 183 - 187
  • [49] ASPLENIA IN A PATIENT WITH SYSTEMIC LUPUS-ERYTHEMATOSUS AND ANTIPHOSPHOLIPID ANTIBODIES
    PETTERSSON, T
    JULKUNEN, H
    JOURNAL OF RHEUMATOLOGY, 1992, 19 (07) : 1159 - 1159
  • [50] ANTIPHOSPHOLIPID ANTIBODIES IN A BRAZILIAN POPULATION WITH SYSTEMIC LUPUS-ERYTHEMATOSUS
    CHAHADE, WH
    STAUB, HL
    KHAMASHTA, M
    HUGHES, GRV
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1989, 7 (04) : 446 - 447